Chiara Signori graduated in Pharmaceutical Biotechnology from Università degli Studi di Milano in 2021, with a thesis conducted at the Mario Negri Research Institute. She then worked at Roche (Basel, Switzerland) on analytical methods for gene therapy products.

In November 2022 she started her PhD at Humanitas University in Milan, which she completed in October 2025.

She now continues her research as a postdoc in the Carlo-Stella group, focusing on predictive biomarkers in patients with aggressive lymphoma.